Study title: Open, controlled, randomised, parallel and multicentre study of the tolerability and the safety of ebastine 2,5 mg once a day in comparison with terfenadine 15 mg twice a day in the sympthomatic treatment of allergic rhinitis and/or allergic conjunctivitis in patients aged from 2 to 5 years old
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Pathological Conditions, Signs and Symptoms | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: EBASTINE | |||||
| ATC code: | |||||
| Document link: 090-103_Ebastine_EUdraCT_reduced datafields-CP-Almirall.xls | |||||
| Document date: 2013-07-24 | |||||
| Study number: 090-103 | |||||
| EudraCT number: | |||||
| Scope of study: | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |